Use of abatacept in rheumatoid arthritis

Use of abatacept in rheumatoid arthritis

Abatacept (CTLA-Ig), a modulator of T-lymphocyte activation, has been approved by the Swiss health regulatory agency Swissmedic for the treatment of active rheumatoid arthritis (RA). This article summarises the key trial findings for this biologic agent in RA in different situations such as ea...

Full description

Bibliographic Details
Main Authors: Johannes von Kempis, Jean Dudler, Paul Hasler, Diego Kyburz, Alan Tyndall, Pascal Zufferey, Peter M. Villiger
Format: Article
Language:English
Published: SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2012-05-01
Series:Swiss Medical Weekly
Subjects:
abatacept
recommendations
rheumatoid arthritis
therapy
use
Online Access:https://www.smw.ch/index.php/smw/article/view/1481

Internet

https://www.smw.ch/index.php/smw/article/view/1481

Similar Items